17 min
Thinking Beyond TROP2 at ESMO 2023 Medscape InDiscussion: Triple-Negative Breast Cancer
-
- Science
What were the biggest takeaways from ESMO 2023 related to TNBC and IBC? Tune in to hear experts Drs Kevin Kalinsky and Filipa Lynce discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Inflammatory Breast Cancer: What You Should Know https://www.medscape.com/viewarticle/778334
Incidence, Characteristics, and Management of Central Nervous System Metastases in Patients With Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36210737/
Inflammatory Breast Cancer Cells Are Characterized by Abrogated Tgfβ1-Dependent Cell Motility and SMAD3 Activity https://pubmed.ncbi.nlm.nih.gov/32043194/
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States https://pubmed.ncbi.nlm.nih.gov/36409824/
Whole-Genome Sequencing of Phenotypically Distinct Inflammatory Breast Cancers Reveals Similar Genomic Alterations to Non-inflammatory Breast Cancers https://pubmed.ncbi.nlm.nih.gov/33902690/
OncoPanel http://cancergeneticslab.ca/genes/oncopanel/
TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI) https://classic.clinicaltrials.gov/ct2/show/NCT05795101
Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer: Results From the NeoSTAR Trial https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.512
The I-SPY Trials https://www.ispytrials.org/
381O First-in-Human/Phase I Trial of HS-20089, a B7-H4 ADC, in Patients With Advanced Solid Tumors https://www.annalsofoncology.org/article/S0923-7534(23)01394-7/fulltext
660MO - First-in-Human Study of SGN-B7H4V, a B7-H4-Directed Vedotin ADC, in Patients With Advanced Solid Tumors: Preliminary Results of a Phase I Study (SGNB7H4V-001) https://oncologypro.esmo.org/meeting-resources/esmo-congress/first-in-human-study-of-sgn-b7h4v-a-b7-h4-directed-vedotin-adc-in-patients-with-advanced-solid-tumors-preliminary-results-of-a-phase-i-study-sg
The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma https://pubmed.ncbi.nlm.nih.gov/37871703/
What were the biggest takeaways from ESMO 2023 related to TNBC and IBC? Tune in to hear experts Drs Kevin Kalinsky and Filipa Lynce discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Inflammatory Breast Cancer: What You Should Know https://www.medscape.com/viewarticle/778334
Incidence, Characteristics, and Management of Central Nervous System Metastases in Patients With Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36210737/
Inflammatory Breast Cancer Cells Are Characterized by Abrogated Tgfβ1-Dependent Cell Motility and SMAD3 Activity https://pubmed.ncbi.nlm.nih.gov/32043194/
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States https://pubmed.ncbi.nlm.nih.gov/36409824/
Whole-Genome Sequencing of Phenotypically Distinct Inflammatory Breast Cancers Reveals Similar Genomic Alterations to Non-inflammatory Breast Cancers https://pubmed.ncbi.nlm.nih.gov/33902690/
OncoPanel http://cancergeneticslab.ca/genes/oncopanel/
TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI) https://classic.clinicaltrials.gov/ct2/show/NCT05795101
Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer: Results From the NeoSTAR Trial https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.512
The I-SPY Trials https://www.ispytrials.org/
381O First-in-Human/Phase I Trial of HS-20089, a B7-H4 ADC, in Patients With Advanced Solid Tumors https://www.annalsofoncology.org/article/S0923-7534(23)01394-7/fulltext
660MO - First-in-Human Study of SGN-B7H4V, a B7-H4-Directed Vedotin ADC, in Patients With Advanced Solid Tumors: Preliminary Results of a Phase I Study (SGNB7H4V-001) https://oncologypro.esmo.org/meeting-resources/esmo-congress/first-in-human-study-of-sgn-b7h4v-a-b7-h4-directed-vedotin-adc-in-patients-with-advanced-solid-tumors-preliminary-results-of-a-phase-i-study-sg
The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma https://pubmed.ncbi.nlm.nih.gov/37871703/
17 min